What the media say about the Stakeholder Discussions:
The news service platform IP-Watch dedicates a series of articles to the event:
- Medicines Innovation and Access: Swiss Stimulate New Thinking
- Do we Need a Global Body to Set Priorities For Diseases and Research?
- Swiss Panel Looks At Value-Based Drug Pricing, Link Between R&D And Prices
This page will be continuously update with the latest news coverage.
Thurs, 1 Feb 2018
IPI, Bern (click here for location)
|9:30 – 10:00||Registration and coffee|
|10:00 – 10:15||Opening and introduction by IPI Deputy Director General Felix Addor|
|10:15 – 11:45||First Panel: New approaches in health innovation for various disease areas and markets – moderated by Alexander Schulze (Swiss Development Cooperation)|
|11:45 – 12:00||Summary of the Panel (moderator and cartoonist)|
|12:00 – 13:15||Lunch break|
|13:15 – 14:45||Second Panel: How to improve availability and affordability of medical products – moderated by Simon Schmid (IPI)|
|14:45 – 15:00|
Summary of the Panel (moderator)
|15:00 – 15:15||Summary of the Day (by Caro van Leeuwen (cartoonist) and Felix Addor)|
|15:15 – 15:20||Closing words by Felix Addor|
|15:20 – 16:00||Networking drinks|
The Swiss Federal Institute of Intellectual Property (IPI) in collaboration with other government agencies is hosting stakeholder discussions to take a closer look at innovation, availability and affordability of medical products in the international context. Is there a discrepancy between health innovation, based on the intellectual property incentive system, and the affordability and availability of medical products? What alternatives do exist?
In two panels, our panellists will debate the pros, cons and implications of various ideas that will suggest keeping, modifying or abolishing the status quo. They will discuss both with each other and with you.
Switzerland is a global leader in the area of innovation – in particular with regard to new and innovative medical products. Consequently, Switzerland has paid a great deal of attention to maintaining an environment that aims at strengthening research, development and marketing of new and innovative medicines. Whilst access and affordability questions have always been part of the equation, in particular with regard to low and middle-income countries, discussions became less heated and relief seemed at hand in the early 2000s with the arrival of the international financing organisation, the Global Fund (to fight AIDS, tuberculosis and malaria). Again, in recent years, the debate has come back into the limelight, including in high-income countries, and in particular with regard to treatment costs for non-communicable diseases and second-generation anti-retroviral drugs, as well as a cure against viral hepatitis C. At the same time, all those involved are aware that important research and development gaps still remain.
The Swiss Federal Institute of Intellectual Property (IPI) in collaboration with other government agencies is hosting stakeholder discussions to take a closer look at innovation, availability and affordability of medical products in the international context. Is there a discrepancy between health innovation, based on the intellectual property incentive system, and the affordability and availability of medical products? Do we need any alternatives and, if so, in what fields of medical products? What alternatives do exist? What are the experiences of various stakeholders and what are their different approaches and recommendations on how to view and deal with potential tensions between health innovation, availability and affordability of medical products? What could new approaches look like?
Our panellists will debate the pros, cons and implications of various ideas that will suggest keeping, modifying or abolishing the status quo. In two panels, representatives from various backgrounds will discuss their visions, the potential challenges and different approaches when it comes to understanding health innovation, availability and affordability of medical products. They will discuss both with each other and with you.
"New approaches in health innovation for various disease areas and markets":
The panellists are invited to focus on health innovation during this first panel. They will debate whether different types of innovation systems and incentives are needed to respond to different types of diseases, catering to various markets and patient segments. It would be interesting to know the results of the current innovation model and whether new ways of incentivising innovation and investment for medical products are needed, and what that might look like.
Dr Peter Beyer, Senior Advisor, Department Of Essential Medicines and Health Products, World Health Organization, Geneva.
Peter Beyer, a trained lawyer, is a Senior Advisor with the WHO in Geneva where he is responsible for issues related to public health, trade and intellectual property. This includes work on innovative funding mechanisms for research and development. Peter was instrumental in setting up a sustainable cooperation among the World Intellectual Property, the World Trade Organization and WHO as well as the WHO/DNDi initiative on a Global Antibiotic R&D Partnership. He is also responsible for the development of a global development and stewardship framework for antimicrobial resistance.
Previously, Peter Beyer was a Legal Advisor to the Swiss Federal Institute of Intellectual Property in Berne. He negotiated bilateral free trade agreements for the European Free Trade Association (EFTA) and headed negotiations at WHO and WIPO. Furthermore, he was responsible for the bilateral dialogue between Switzerland and China on intellectual property.
Pascale Boulet joined DNDi in November 2008 as Intellectual Property & Policy Advisor and acted as Head of Policy Affairs in 2012-2013. In 2017, Pascale became Intellectual Property & Access Leader, with the Business Development team.
Pascale is a lawyer with 20 years of experience in intellectual property laws and policies, with a particular focus on pharmaceuticals. Prior to joining DNDi, Pascale acted as senior legal advisor of MSF Access Campaign and technical officer with WHO Medicines Department. Besides her part-time work at DNDi, Ms Boulet works as an independent consultant with various public health organizations.
Pascale earned a Master in International Economic Law from the University of Panthéon-Sorbonne in Paris, and a Certificate in Public Health and Primary Health Care in Developing Countries from University of Medicine of Montpellier, France.
Margaret Kyle (MINES ParisTech and CEPR) studies innovation, productivity and competition. She has a number of papers examining R&D productivity in the pharmaceutical industry, specifically the role of geographic and academic spillovers; the firm-specific and policy determinants of the diffusion of new products; generic competition; and the use of markets for technology. Recent work examines the effect of trade and IP policies on the level, location and direction of R&D investment and competition. She also works on issues of innovation and access to therapies in developing countries. Her papers have been published in various journals of economics, strategy, and health policy, including the RAND Journal of Economics, Review of Economics and Statistics, Journal of Law and Economics, Strategic Management Journal, Health Services Research, and Health Affairs.
Margaret holds a PhD in economics from the Massachusetts Institute of Technology. She previously held positions at Carnegie Mellon University, Duke University, London Business School, and the Toulouse School of Economics, and is a visiting professor at the Kellogg School of Management, Northwestern University. She has also been a visiting scholar at the Center for the Study of Innovation and Productivity at the Federal Reserve Bank of San Francisco and at the University of Hong Kong.
Peter Braun is in charge of Global Access Strategy and Health Policy at Roche in Switzerland. In this role, Braun is responsible for the development of global health policy, and patient access strategies across the organisation. Braun’s career at Roche began in 1991 and has spanned a variety of global, regional and affiliate roles across developed as well as emerging countries (US, Mexico, Belgium, The Netherlands, and Peru). In particular, as Lifecycle Leader of Herceptin and Tarceva, he led teams through multiple clinical study readouts as well as two global regulatory approvals. Prior to his current role, he worked as Roche’s General Manager of Peru. Braun holds an MBA from INSEAD and undergraduate degrees from the University of Pennsylvania and the Wharton School of Business.
"How to improve availability and affordability of medical products"
The panellists are invited to focus on availability and affordability of medical products. They will debate how availability and affordability of medical products can be improved whilst making sure that the pipeline for future innovative products will continue to deliver. We will hear about their perspective on the relationship between the current patent-based innovation model, as well as the availability and affordability of medical products. What other factors should be addressed to improve availability and affordability of medical products?
Esteban Burrone is the Head of Policy of the Medicines Patent Pool, an institution set up in 2010 to promote access to affordable and appropriate HIV, HCV and TB medicines in developing countries, through the licensing of key patents. As Head of Policy, Esteban works on partnerships with a large number of organizations and stakeholders, including governments, intergovernmental organizations and civil society organizations. He has over 15 years of experience working in the field of intellectual property rights and access to medicines in developing countries. Esteban holds a Masters degree in Development Studies and a Masters in Business Administration (MBA). Before joining UNITAID to work on the establishment of the Medicines Patent Pool in 2010, Esteban worked at the World Intellectual Property Organization (WIPO).
Christophe Carbonel is the Head of Market Pricing, overlooking worldwide pricing and access implementation at Novartis Pharma AG, Basel.
Christophe trained as a physician at Paris Medical School, earned an MBA at Groupe HEC in Paris and has over 25 year experience in the Pharmaceutical industry with 17 year experience in the pricing and access of pharmaceuticals. He created the global strategic pricing function at Novartis integrating the needs of payers into development programs. More recently Christophe held the position of Head of Pricing and Market Access in Japan, negotiating access for more than 10 different brands with Japanese authorities.
In his current role Christophe has a multi-regional view of the impact of various healthcare policies (and more specifically of Pricing and Reimbursement policies) on patient access to medicines, reward and incentive for innovation brought by pharmaceuticals and contribution of pharmaceuticals to the efficiency of healthcare delivery. The Market Pricing group supports the design of managed entry agreements to address payers’ questions around the level of evidence supporting the value of our drugs, the degree of budget impact or to address affordability. Finally Market Pricing is fostering dialogue between Novartis and payers or their advisors through various regional idea sharing platforms.
Ellen ‘t Hoen is a lawyer and public health advocate with over 30 years of experience working on pharmaceutical and intellectual property policies. She works as an independent consultant in medicines law and policy for a number of international organisations and governments and is a researcher at the Global Health Unit of the University Medical Centre Groningen, The Netherlands.
From 1999 until 2009 she was the director of policy for Médecins sans Frontières’ Campaign for Access to Essential Medicines. In 2009 she joined UNITAID in Geneva to set up the Medicines Patent Pool (MPP), an initiative that negotiates patent licenses with pharmaceutical companies to ensure access to affordable generic medicines for the treatment of HIV, TB and HCV. Her TED Talk about the Medicines Patent Pool is available here. She was the MPP’s first executive director until 2012.
She is a member of the Lancet Commission on Essential Medicines Policies, the Advisory Board of Universities Allied for Essential Medicines (UAEM) and the Editorial Board of the Journal of Public Health Policy.
In 2005, 2006, 2010 and 2011 she was listed as one of the 50 most influential people in intellectual property by the journal Managing Intellectual Property.
She has published widely and is the author of several books. In 2017 she received the Prix Prescrire for her latest book “Private Patents and Public Health: Changing intellectual property rules for public health.”.
Jürg’s 30 career with EY has involved extensive audit and corporate
finance experience with local and international health/life sciences
clients. He is currently serving as Lead Audit Partner for AC Immune SA,
Abbott (EPD), AbbVie, BioMedinvest I&II, CRISPR Therapeutics AG and
has served in this role on Actelion, Evolva, Roche, Santhera
Pharmaceuticals, Syngenta, Synthes and HBM Healthcare Investments.
His experience of having worked with EY in the United States has helped
him to also successfully transition clients to International Reporting
Standards (IFRS or U.S. GAAP). He is now the partner responsible for the
EY biotech/medtech sector in GSA.
In addition to serving as an audit partner to several venture capital
companies, Jürg Zürcher is also active in the VC community, advising
clients on fundraising opportunities and facilitating mergers. His rich
understanding of the biotech market in the region was instrumental in
providing the Swiss federal government with an in-depth analysis of the
state of biotechnology in Switzerland and the launch of the
1st Swiss biotechnology report in March 2004.
Jürg Zürcher studied at the University of St. Gallen, where he obtained a
Master in Business Administration, with focus on auditing.
Swiss Certified Accountant.
Felix Addor serves as the Deputy Director General, General Counsel and Director of the Legal and International Affairs Division at the Swiss Federal Institute of Intellectual Property (Swiss Ministry of Justice), the federal agency in charge of all intellectual property matters in Switzerland (www.ige.ch). He has been responsible for legal and policy matters regarding all fields of intellectual property at the national and international level since 1999. He leads Swiss negotiating delegations to the relevant international fora, such as the World Trade Organization and the World Intellectual Property Organization, and to bi- and plurilateral negotiations. Since 2008, Prof. Addor has been a Professor at the Faculty of Law, University of Bern, too. He lectures on intellectual property law, international negotiations and global governance at the University of Bern, the World Trade Institute, and the Graduate Institute Geneva, among others.
Caro van Leeuwen grew up in the Netherlands and in Switzerland. After her Master in African Studies she worked as an intern at the Swiss Agency for Development and Cooperation (SDC) in the Global Programme Health where she also (re)discovered drawing as a communication tool. During her internship and since then she has documented and summarised various projects visually with posters or videos. Her main occupation is in the area of migration and integration.
Alexander Schulze, Ph.D., M.A., is a sociologist with a postgraduate Diploma in Development Co-operation. He has served as a Co-Head of the division Global Programme Health at the Swiss Agency for Development and Cooperation (SDC) since July 2016. His areas of work include access to health care and medical products, social health protection and health financing as well as health product research and development.
He joined SDC as a Senior Advisor for Health Systems Strengthening and Financing in 2014. Previously, he held various positions such as Access Program and Research Manager at the Novartis Foundation in Basel. Schulze is currently member of the Advisory Council to the Lancet Global Health Commission on High-Quality Health Systems.
Simon has been working for IPI since 2009. He serves as a regular advisor to and member of the Swiss delegation to the World Health Organization (WHO) in the areas of IP, innovative health financing & regulatory issues. For more than eight years, he negotiated free trade agreements with mainly emerging markets on behalf of the European Free Trade Association (EFTA). For six years, he was responsible for a bilateral IP dialogue between the Chinese and Swiss government and institutionalised a public-private roundtable. In 2016, Simon worked for the World Health Organization (WHO) for four months, helping to prepare and set up the WHO Fair Pricing Forum in its initial project phase.
Simon is a recent graduate from Seth Godin’s altMBA and has a MA in international law and economics from the World Trade Institute and a MA in international relations from the Graduate Institute of International and Development Studies. Previously, he had worked in private banking for Credit Suisse.
Swiss Federal Institute of Intellectual Property (IPI) – with the involvement of other government agencies
Simon Schmid (email@example.com)
Swiss Federal Institute of Intellectual Property (IPI), Stauffacherstrasse 65/59g, Bern (IPI)
Thurs, 1 Feb 2018
20.03.2018 | ip-news
Patentanmeldungen aus der Schweiz sind 2017 auf neue Höchstmarke gestiegen
Informationsveranstaltung zur Nutzung von strategischen Patentanalysen am 11.4.2018 in Zürich
Informationsveranstaltung zur Nutzung von strategischen Patentanalysen am 11.4.2018 in Zürich
14.02.2018 | Veranstaltung
Stakeholder Discussions on: Innovation, availability and affordability of medical products. Can we achieve it all?
Seminar IPI / LES: „Neueste Entwicklungen im Markenrecht“ am 9. November in Genf
Regiosuisse Tagung „Regionale Innovationsförderung und WTT: Angebote und ihr Nutzen für die Wirtschaft“ 06.09.2017 09:00-16:30, Bern